HC Wainwright Increases Eton Pharmaceuticals (NASDAQ:ETON) Price Target to $17.00

Eton Pharmaceuticals (NASDAQ:ETON) had its price target increased by analysts at HC Wainwright from $15.00 to $17.00 in a report issued on Monday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 41.78% from the company’s previous close.

Separately, Craig Hallum raised their price objective on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, October 28th.

Eton Pharmaceuticals Stock Down 1.4 %

Shares of ETON opened at $11.99 on Monday. The company has a market capitalization of $312.35 million, a price-to-earnings ratio of -54.50 and a beta of 1.38. Eton Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $15.00. The stock’s 50-day moving average price is $11.51 and its 200-day moving average price is $7.28.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ETON. Thompson Siegel & Walmsley LLC acquired a new position in shares of Eton Pharmaceuticals during the 2nd quarter worth approximately $420,000. Renaissance Technologies LLC raised its position in Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after acquiring an additional 41,469 shares during the period. Nantahala Capital Management LLC purchased a new position in Eton Pharmaceuticals during the second quarter valued at $3,095,000. Stonepine Capital Management LLC acquired a new stake in shares of Eton Pharmaceuticals in the second quarter valued at about $362,000. Finally, Aristides Capital LLC purchased a new stake in shares of Eton Pharmaceuticals during the second quarter worth about $658,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.